Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.31 |
| ▸ | FEN1 | P39748 | 2/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.30 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26604960 | 1.00 | AURKA (0.38) | AURKATTKAURKBINCENPMAPT | |
| SCHEMBL2790586 | 0.77 | MAPT (0.35) | AURKATTKAURKBINCENPMAPT | |
| SCHEMBL20702438 | 0.77 | MAPT (0.35) | AURKATTKAURKBINCENPMAPT | |
| SCHEMBL21246893 | 0.77 | AURKA (0.38) | AURKATTKAURKBINCENPMAPT | |
| SCHEMBL31046685 | 0.74 | AURKA (0.44) | AURKATTKAURKBINCENPMAPT | |
| SCHEMBL30645955 | 0.73 | — | — | |
| SCHEMBL25230769 | 0.72 | AURKA (0.33) | AURKATTKAURKBINCENPMAPT | |
| SCHEMBL31015914 | 0.72 | AURKA (0.33) | AURKATTKAURKBINCENPMAPT | |
| SCHEMBL19783681 | 0.71 | AURKA (0.42) | AURKATTKAURKBINCENPMAPT | |
| SCHEMBL16923272 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116891-A1 | Oxazepin Derivative | TEIJIN PHARMA LTD (JP) | 2026-04-30 | — | — | US | disclosed |
| EP-4512811-A1 | OXAZEPINE DERIVATIVE | Teijin Pharma Limited (JP) | 2025-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116891-A1 | Oxazepin Derivative | HCRTR2, HCRTR1, OXTR | AURKA 3190/4885TTK 3957/4885AURKB 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.